




SUPPLEMENTARY FIGURES



Supplementary Figure 1. Western blotting assay for PV in frontal cortex and hippocampal tissue in control mice of ALS mice at different periods. \*\*\* $P < 0.001$  vs. control at 90~100 days. ### $P < 0.001$  vs. control at 130~140 days. In all experiments, half male and half female mice were in each group ( $n = 6$ ).



Supplementary Figure 2. Immunofluorescence of FaMNs with marker of MMP-9<sup>+</sup> and ChAT-GFP<sup>+</sup> in at different periods. \*\*\* $P < 0.001$  vs. control at 90~100 days. ### $P < 0.001$  vs. control at 130~140 days. In all experiments, half male and half female mice were in each group ( $n = 6$ ).



**Supplementary Figure 3. Western blotting assay for expression of PV, ErbB4 and MMP-9 in ALS mice treated with different dose of NRG1 at 130~140 days.** \*\*\* $P < 0.001$  vs. control. In all experiments, half male and half female mice were in each group ( $n = 6$ ).